Article Published in American Journal of Cardiology Demonstrates Safety And Effectiveness of Excimer Laser Coronary Angioplasty To Treat Patients During Acute Coronary Syndromes

Apr 10, 2001, 01:00 ET from Spectranetics Corporation

    COLORADO SPRINGS, Colo., April 10 /PRNewswire/ -- The Spectranetics
 Corporation (Nasdaq:   SPNC) today announced the publication of an article in
 the April 1, 2001 issue of the American Journal of Cardiology demonstrating
 the safety and effectiveness of excimer laser coronary angioplasty to treat a
 subset of patients with acute coronary syndromes.
     The article entitled "Effectiveness of Excimer Laser Coronary Angioplasty
 in Acute Myocardial Infarction or in Unstable Angina Pectoris" evaluated the
 feasibility, safety, and acute results of percutaneous excimer laser coronary
 angioplasty (ELCA) in acute coronary syndromes.  Fifty-nine patients were
 treated with ELCA, including 33 patients with unstable angina pectoris (UAP)
 and 26 patients with acute myocardial infarction (AMI).  The study showed
 procedural success rates of 100 percent and 97 percent for the AMI and UAP
 groups respectively.  Two thirds of patients in the UAP group (with no
 presence of thrombus) fall within Spectranetics' indications for use and were
 safely and effectively treated with the laser followed by balloon angioplasty.
 Spectranetics presently contraindicates excimer laser angioplasty in AMI and
 acute thrombosis.  The patients in the AMI group were treated in accordance
 with accepted medical standards, published medical literature and the
 Declaration of Helsinki.  All patients gave written informed consent.
     On Topaz, M.D., FACC, of the Medical College of Virginia Hospitals,
 Virginia Commonwealth University, Richmond, Virginia, the lead study
 investigator, commented: "The findings in the study support the application of
 excimer laser angioplasty in selected patients with complex lesions who
 present with acute coronary syndromes.  Furthermore, the findings suggest that
 ultraviolet laser therapy results in thrombus removal and a high procedural
 success rate with minimal complications.  Further study is necessary to
 compare the laser to other approaches to treat acute coronary syndromes."
     Joseph A. Largey, president and chief executive officer of Spectranetics
 commented:  "This impressive study presents new data supporting the safety and
 efficacy of excimer laser angioplasty within our six PMA indications in
 patients with unstable angina.  We are interested in the new data presented in
 the investigators' research showing that the laser resulted in significant
 thrombus removal, suggesting direct laser energy absorption and thrombus
 vaporization."
     Laser catheters used in this study included Spectranetics' new OS catheter
 technology.  A recent paper in the February 2001 issue of the Journal of
 Clinical Laser Medicine and Surgery (Vol. 19, No. 1, pp. 9-14) by Topaz, et.
 al. entitled "Optimally Spaced Excimer Laser Coronary Catheters: Performance
 Analysis" described the improved ablation capability of this new catheter
 technology.  Dr. Topaz commented that "the use of this new technology and the
 application of appropriate lasing techniques leads to positive clinical
 results such as those seen in our study published in the American Journal of
 Cardiology."
 
     Spectranetics is a medical device company that develops, manufactures and
 markets products that deliver excimer laser energy for minimally invasive
 surgical procedures within the cardiovascular system.  The company's
 CVX-300(R) excimer laser is the only system approved by the Food and Drug
 Administration (FDA) for multiple cardiovascular procedures, including
 coronary angioplasty and the removal of problematic pacemaker and
 defibrillator leads.  The company is currently conducting three
 investigational trials designed to obtain FDA approval to market products in
 the United States for additional applications.  The LACI study (Laser
 Angioplasty for Critical Ischemia) tests laser angioplasty to improve
 circulation in the lower leg.  The PELA trial (Peripheral Excimer Laser
 Angioplasty) deals with blockages in arteries in the upper leg.  LARS (Laser
 Angioplasty for Restenosed Stents) tests use of excimer laser energy to clear
 blocked coronary stents (thin steel mesh tubes used to support the walls of
 coronary arteries).  All of the company's FDA-approved and investigational
 applications have received Communaute Europeene (CE) mark registration for
 marketing within Europe.
 
     This news release contains forward-looking statements within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934.  Such statements are based on current assumptions that
 involve risks and uncertainties that could cause actual outcomes and results
 to differ materially.  These risks and uncertainties may include increasing
 price and product competition, dependence on new product development,
 intellectual property claims of third parties, availability of inventory from
 suppliers, timeliness of FDA approval to market new products or applications,
 market acceptance of new products or applications, and product defects.  For a
 further list and description of such risks and uncertainties which could cause
 the actual results, performance or achievements of the company to be
 materially different from any anticipated results, performance or
 achievements, please see the company's previously filed SEC reports.
 Spectranetics disclaims any intention or obligation to update or revise any
 financial projections or forward-looking statements, whether as a result of
 new information, future events or otherwise.
 
     Spectranetics and CVX-300 are registered trademarks of The Spectranetics
 Corporation.
 
 

SOURCE Spectranetics Corporation
    COLORADO SPRINGS, Colo., April 10 /PRNewswire/ -- The Spectranetics
 Corporation (Nasdaq:   SPNC) today announced the publication of an article in
 the April 1, 2001 issue of the American Journal of Cardiology demonstrating
 the safety and effectiveness of excimer laser coronary angioplasty to treat a
 subset of patients with acute coronary syndromes.
     The article entitled "Effectiveness of Excimer Laser Coronary Angioplasty
 in Acute Myocardial Infarction or in Unstable Angina Pectoris" evaluated the
 feasibility, safety, and acute results of percutaneous excimer laser coronary
 angioplasty (ELCA) in acute coronary syndromes.  Fifty-nine patients were
 treated with ELCA, including 33 patients with unstable angina pectoris (UAP)
 and 26 patients with acute myocardial infarction (AMI).  The study showed
 procedural success rates of 100 percent and 97 percent for the AMI and UAP
 groups respectively.  Two thirds of patients in the UAP group (with no
 presence of thrombus) fall within Spectranetics' indications for use and were
 safely and effectively treated with the laser followed by balloon angioplasty.
 Spectranetics presently contraindicates excimer laser angioplasty in AMI and
 acute thrombosis.  The patients in the AMI group were treated in accordance
 with accepted medical standards, published medical literature and the
 Declaration of Helsinki.  All patients gave written informed consent.
     On Topaz, M.D., FACC, of the Medical College of Virginia Hospitals,
 Virginia Commonwealth University, Richmond, Virginia, the lead study
 investigator, commented: "The findings in the study support the application of
 excimer laser angioplasty in selected patients with complex lesions who
 present with acute coronary syndromes.  Furthermore, the findings suggest that
 ultraviolet laser therapy results in thrombus removal and a high procedural
 success rate with minimal complications.  Further study is necessary to
 compare the laser to other approaches to treat acute coronary syndromes."
     Joseph A. Largey, president and chief executive officer of Spectranetics
 commented:  "This impressive study presents new data supporting the safety and
 efficacy of excimer laser angioplasty within our six PMA indications in
 patients with unstable angina.  We are interested in the new data presented in
 the investigators' research showing that the laser resulted in significant
 thrombus removal, suggesting direct laser energy absorption and thrombus
 vaporization."
     Laser catheters used in this study included Spectranetics' new OS catheter
 technology.  A recent paper in the February 2001 issue of the Journal of
 Clinical Laser Medicine and Surgery (Vol. 19, No. 1, pp. 9-14) by Topaz, et.
 al. entitled "Optimally Spaced Excimer Laser Coronary Catheters: Performance
 Analysis" described the improved ablation capability of this new catheter
 technology.  Dr. Topaz commented that "the use of this new technology and the
 application of appropriate lasing techniques leads to positive clinical
 results such as those seen in our study published in the American Journal of
 Cardiology."
 
     Spectranetics is a medical device company that develops, manufactures and
 markets products that deliver excimer laser energy for minimally invasive
 surgical procedures within the cardiovascular system.  The company's
 CVX-300(R) excimer laser is the only system approved by the Food and Drug
 Administration (FDA) for multiple cardiovascular procedures, including
 coronary angioplasty and the removal of problematic pacemaker and
 defibrillator leads.  The company is currently conducting three
 investigational trials designed to obtain FDA approval to market products in
 the United States for additional applications.  The LACI study (Laser
 Angioplasty for Critical Ischemia) tests laser angioplasty to improve
 circulation in the lower leg.  The PELA trial (Peripheral Excimer Laser
 Angioplasty) deals with blockages in arteries in the upper leg.  LARS (Laser
 Angioplasty for Restenosed Stents) tests use of excimer laser energy to clear
 blocked coronary stents (thin steel mesh tubes used to support the walls of
 coronary arteries).  All of the company's FDA-approved and investigational
 applications have received Communaute Europeene (CE) mark registration for
 marketing within Europe.
 
     This news release contains forward-looking statements within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934.  Such statements are based on current assumptions that
 involve risks and uncertainties that could cause actual outcomes and results
 to differ materially.  These risks and uncertainties may include increasing
 price and product competition, dependence on new product development,
 intellectual property claims of third parties, availability of inventory from
 suppliers, timeliness of FDA approval to market new products or applications,
 market acceptance of new products or applications, and product defects.  For a
 further list and description of such risks and uncertainties which could cause
 the actual results, performance or achievements of the company to be
 materially different from any anticipated results, performance or
 achievements, please see the company's previously filed SEC reports.
 Spectranetics disclaims any intention or obligation to update or revise any
 financial projections or forward-looking statements, whether as a result of
 new information, future events or otherwise.
 
     Spectranetics and CVX-300 are registered trademarks of The Spectranetics
 Corporation.
 
 SOURCE  Spectranetics Corporation